Project Grant R03CA293129
Award Date 7/3/24
Completion Date 6/30/26
Dollars Obligated $162K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lubbock, TX 79409, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a project grant of $402,011 to The University of Texas Southwestern Medical Center under the Cancer Biology Research program (CFDA 93.396) beginning May 1, 2026 and concluding April 30, 2031. This five-year award supports fundamental research investigating the role of the KEAP1-NRF2 (Kelch-like ECH-associated protein 1-Nuclear factor erythroid 2-related factor 2) redox-sensing pathway in regulating CD8 T cell...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $150,898 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Texas at Austin, effective June 8, 2026, with completion targeted for May 30, 2028. This two-year research initiative focuses on identifying and validating novel molecular regulators of cell-cell fusion in triple negative breast cancer (TNBC), which represents 15-20% of diagnosed breast cancers and currently lacks targeted...
- This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under CFDA Program 93.310 - Trans-NIH Research Support, provides $1,476,000.00 to The University of Texas Southwestern Medical Center to develop and apply innovative tools to study the role of subcellular redox circuits in tumor metastasis. The project aims to address key questions about how highly metastatic tumors overcome oxidative stress, using advanced in vivo optogenetic approaches,...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University $621,574 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate mitochondrial reprogramming mechanisms in tumor-associated macrophages (TAMs) as a strategy to counteract immunosuppression in the tumor microenvironment. The five-year project, extending through June 30, 2031, will deliver fundamental research addressing how AMP-activated protein kinase (AMPK)...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $639,514 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026, through May 31, 2031. This award supports fundamental research aimed at characterizing the catalytic mechanisms of NVL (a critical AAA+ ATPase enzyme) and evaluating how benzothiazepinone compounds—specifically MM17—inhibit ribosome biogenesis as a novel...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Grant Award Summary Texas Tech University received a $607,488 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for the period June 1, 2026 through May 31, 2029. The award supports the development and validation of the HU microchip platform—an innovative microfluidic device designed to isolate and profile circulating tumor cells (CTCs) with specific epithelial-mesenchymal transition (EMT) markers. The project...
- Federal Project Grant Award Summary The Medical University of South Carolina received a $153,768 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), effective September 10, 2025, through July 31, 2028. This award supports research training and investigator development focused on elucidating the role of peroxisome biogenesis in enhancing anti-tumor T cell metabolic fitness and immune function. The grant funds a research initiative...
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), awarded a $456,500 Project Grant to The University of Texas Southwestern Medical Center effective April 1, 2026, through January 31, 2031. This award supports fundamental research aimed at elucidating the structural mechanisms and transport properties of the mitochondrial pyruvate carrier (MPC), a critical protein complex...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $680,129 Project Grant to The University of Texas M.D. Anderson Cancer Center under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026 through March 31, 2031. This award supports the development of drug-loaded degradable biopolymeric scaffolds designed to augment preoperative liver growth in cancer patients undergoing hepatic resection. The project addresses critical clinical challenges...